Morris Laster, M.D.
Chairman and Chief Executive Officer
Dr. Laster serves as Keryx's Chairman and Chief Executive Officer. He was previously employed as Vice President of Medical Venture Capital with Paramount Capital Investments LLC., a New York-based biotechnology venture group. Dr Laster was also a founder of a number of privately held and publicly traded biotechnology companies including Neose Technologies, a publicly traded NASDAQ company. Dr. Laster received his M.D. from Downstate Medical Center, performed post-doctoral training in surgery at Case Western Reserve University Hospital and served as a physician and officer with the paratroopers of the Israel Defense Forces.

Benjamin Corn, M.D.
President
Professor Corn serves as Keryx's President. He previously served as Professor and Vice-Chairman in the Department of Radiation Oncology at Thomas Jefferson University Hospital in Philadelphia. Professor Corn received his B.A. and M.D. degrees from Boston University and completed residency training at the University of Pennsylvania, where he later served as Assistant Professor of Radiation Oncology.

Robert E. Gallahue
Chief Financial Officer and Treasurer
Mr. Gallahue recently joined Keryx from Millennium Pharmaceuticals where he served as Senior Director, Finance. From November 1993 to December 1999, he served as Controller and then Senior Director, Finance at LeukoSite, Inc. until its recent merger with Millennium Pharmaceuticals. From 1989 to 1993, Mr. Gallahue served as Accounting Manager and then Senior Financial Analyst at RepliGen Inc. From 1985 to 1989, he was an auditor at Coopers & Lybrand. Mr. Gallahue received his B.A. from Middlebury College and his M.S.A. from Bentley College and is a certified public accountant.

Ira Weinstein
Chief Operating Officer
Dr. Weinstein serves as Keryx's Chief Operating Officer. Prior to this, he was an accountant with the Association of Americans and Canadians in Israel. He has also served as a consultant to the New York State Department of Health and taught business management at Baruch College, Touro College and St. John's University. Dr. Weinstein holds a Doctorate of Business Administration from Newport University and an M.B.A. in Management and a B.B.A. in Accountancy from Baruch College.

Bob Trachtenberg
General Counsel and Secretary
Mr. Trachtenberg serves as Keryx's General Counsel and Secretary. He was previously the Senior Vice President for Administration and Legal Affairs at Accent Software International, Ltd. (now known as LanguageWare, net, Ltd.), a publicly traded software development company. Mr. Trachtenberg received his B.A. from the State University of New York at Binghamton and his J.D. from New York University.

Noa Shelach, M.Sc.
Director of Project Management
Ms. Shelach serves as Keryx's Director of Project Management, responsible for coordinating and managing the clinical development of KRX-101, as well as supervising the managers of other company projects. She received her B.Sc. in Biology and M.Sc. in Biochemistry from the Hebrew University in Jerusalem and has completed a two-year course in clinical pharmacology at Tel Aviv University. She recently participated in a Pharmaceutical and Education Research Institute (PERI) course for Physicians and Scientists for Drug Development in Arlington, Virginia.